<p>ANI 製藥公司（NASDAQ:ANIP - 獲取免費報告）的股票在週一的午盤交易中因內部人士出售活動下跌了 3.6%。該股最低交易價格為 79.36 美元，最後交易價格為 79.8450 美元。在交易中大約有 86,438 股成交，較平均每日成交量 377,608 股下降了 77%。該股此前收盤價為 82.85 美元。</p>
<p>獲取 <strong>ANI 製藥</strong> 的提醒：</p>
<p>具體來説，高級副總裁 Krista Davis 在 12 月 18 日星期四出售了 1,622 股公司的股票，交易的平均價格為 82.40 美元，總交易額為 133,652.80 美元。交易完成後，這位高級副總裁直接持有公司 58,564 股，價值 4,825,673.60 美元。此次交易使其持股比例減少了 2.69%。該出售在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。</p>
<h2>分析師評級變動</h2>
<p>ANI 製藥已成為多份研究分析師報告的主題。Guggenheim 在 11 月 10 日的報告中將 ANI 製藥的目標價格從 114.00 美元上調至 115.00 美元，並給予該公司 “買入” 評級。HC Wainwright 在 9 月 17 日的研究報告中將 ANI 製藥的目標價格從 93.00 美元上調至 121.00 美元，並給予該股 “買入” 評級。巴克萊在 12 月 9 日的研究報告中開始覆蓋 ANI 製藥，給予 “增持” 評級和 100.00 美元的目標價格。Truist Financial 在 10 月 9 日的研究報告中將 ANI 製藥的目標價格從 77.00 美元上調至 90.00 美元，並給予該公司 “持有” 評級。最後，Weiss Ratings 在 12 月 15 日的報告中將 ANI 製藥的評級從 “買入（b-）” 下調至 “持有（c+）”。一位研究分析師給予該股 “強烈買入” 評級，六位分析師給予 “買入” 評級，兩位分析師給予 “持有” 評級。根據 MarketBeat 的數據，ANI 製藥的平均評級為 “適度買入”，平均目標價格為 102.14 美元。</p>
<p><strong>查看我們對 ANI 製藥的最新分析</strong></p>
<h2>ANI 製藥股票下跌 3.6%</h2>
<p>該股市值為 17.9 億美元，市盈率為 49.04，貝塔值為 0.48。公司流動比率為 2.04，當前比率為 2.58，債務股本比率為 1.20。該股的 50 日移動平均價格為 86.70 美元，200 日移動平均價格為 81.62 美元。</p>
<p>ANI 製藥（NASDAQ:ANIP - 獲取免費報告）最近在 11 月 7 日發佈了季度財報。這家專業製藥公司報告每股收益（EPS）為 2.04 美元，超出分析師一致預期的 1.74 美元，超出幅度為 0.30 美元。ANI 製藥的淨利潤率為 4.91%，股本回報率為 26.73%。該公司在本季度的收入為 2.2781 億美元，而分析師預期為 2.1192 億美元。去年同期，該公司每股收益為 1.34 美元。該公司的季度收入同比增長 53.6%。ANI 製藥已將 2025 財年的指導目標設定為每股收益 7.370-7.640 美元。整體來看，分析師預測 ANI 製藥將在當前年度發佈每股收益 3.86 美元。</p>
<h2>ANI 製藥的機構交易</h2>
<p>幾家機構投資者最近調整了對該公司的持股。Intech Investment Management LLC 在第二季度將其在 ANI 製藥的持股增加了 134.7%。Intech Investment Management LLC 目前持有 26,917 股該專業製藥公司的股票，價值 1,756,000 美元，此前在上個季度購買了 15,447 股。Envestnet Asset Management Inc.在第二季度將其在 ANI 製藥的持股增加了 59.9%。Envestnet Asset Management Inc.目前持有 10,326 股該專業製藥公司的股票，價值 674,000 美元，此前在上個季度購買了 3,869 股。Squarepoint Ops LLC 在第二季度獲得了 ANI 製藥的新頭寸，價值 2,137,000 美元。Dynamic Technology Lab Private Ltd 在第二季度獲得了 ANI 製藥的新頭寸，價值 209,000 美元。最後，Sio Capital Management LLC 在第二季度將其在 ANI 製藥的持股增加了 29.4%。Sio Capital Management LLC 目前持有 112,923 股該專業製藥公司的股票，價值 7,368,000 美元，此前在上個季度購買了 25,625 股。機構投資者持有該公司 76.05% 的股票。</p>
<h2>ANI 製藥公司簡介</h2>
<p>（獲取免費報告）</p>
<p>ANI 製藥公司是一家總部位於美國的專業製藥公司，專注於仿製藥和品牌處方藥的開發、生產和商業化。該公司作為一個端到端的提供商，提供從活性藥物成分（API）生產和配方開發到成品劑型製造和包裝的服務。</p>
<p>ANI 的產品組合涵蓋了多個治療領域的注射和口服療法，包括內分泌學、腫瘤學、疼痛管理和呼吸護理。</p>
<h2>特色故事</h2>
<ul>
<li>五隻我們更看好的股票超過 ANI 製藥</li>
<li>美聯儲轉向信號，聰明資金一直在等待</li>
<li>這家 AI-量子公司預計 2025 年收入將達到 2.74 億美元</li>
<li>華爾街股票挑選者命名 2026 年第一隻股票</li>
<li>請勿刪除，立即閲讀</li>
<li>“客户銀行存款 660 億美元面臨風險”</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 ANI 製藥嗎？</h2>
<p>在考慮 ANI Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 ANI Pharmaceuticals 並不在名單上。</p>
<p>雖然 ANI Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ANI制藥

<p>ANI 製藥（NASDAQ:ANIP）的股票因高級副總裁 Krista Davis 出售 1,622 股而下跌 3.6%。該股票交易低點為 79.36 美元，交易量顯著下降。儘管出現下滑，分析師仍維持 “適度買入” 評級，平均目標價為 102.14 美元。該公司報告了強勁的季度收益，超出預期，市值為 17.9 億美元</p>

<p>Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) were down 3.6% during mid-day trading on Monday following insider selling activity. The stock traded as low as $79.36 and last traded at $79.8450. Approximately 86,438 shares traded hands during trading, a decline of 77% from the average daily volume of 377,608 shares. The stock had previously closed at $82.85.</p>
<div class="lb-trans"><p>ANI 製藥公司（NASDAQ:ANIP - 獲取免費報告）的股票在週一的午盤交易中因內部人士出售活動下跌了 3.6%。該股最低交易價格為 79.36 美元，最後交易價格為 79.8450 美元。在交易中大約有 86,438 股成交，較平均每日成交量 377,608 股下降了 77%。該股此前收盤價為 82.85 美元。</p>
</div><p>Get <strong>ANI Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>ANI 製藥</strong> 的提醒：</p>
</div><p>Specifically, SVP Krista Davis sold 1,622 shares of the business's stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $82.40, for a total transaction of $133,652.80. Following the completion of the transaction, the senior vice president directly owned 58,564 shares in the company, valued at $4,825,673.60. The trade was a 2.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link.</p>
<div class="lb-trans"><p>具體來説，高級副總裁 Krista Davis 在 12 月 18 日星期四出售了 1,622 股公司的股票，交易的平均價格為 82.40 美元，總交易額為 133,652.80 美元。交易完成後，這位高級副總裁直接持有公司 58,564 股，價值 4,825,673.60 美元。此次交易使其持股比例減少了 2.69%。該出售在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>ANIP has been the topic of a number of research analyst reports. Guggenheim raised their target price on ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a &#34;buy&#34; rating in a report on Monday, November 10th. HC Wainwright upped their price objective on ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, September 17th. Barclays initiated coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an &#34;overweight&#34; rating and a $100.00 price objective on the stock. Truist Financial lifted their target price on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a &#34;hold&#34; rating in a research report on Thursday, October 9th. Finally, Weiss Ratings cut shares of ANI Pharmaceuticals from a &#34;buy (b-)&#34; rating to a &#34;hold (c+)&#34; rating in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, ANI Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and an average price target of $102.14.</p>
<div class="lb-trans"><p>ANI 製藥已成為多份研究分析師報告的主題。Guggenheim 在 11 月 10 日的報告中將 ANI 製藥的目標價格從 114.00 美元上調至 115.00 美元，並給予該公司 “買入” 評級。HC Wainwright 在 9 月 17 日的研究報告中將 ANI 製藥的目標價格從 93.00 美元上調至 121.00 美元，並給予該股 “買入” 評級。巴克萊在 12 月 9 日的研究報告中開始覆蓋 ANI 製藥，給予 “增持” 評級和 100.00 美元的目標價格。Truist Financial 在 10 月 9 日的研究報告中將 ANI 製藥的目標價格從 77.00 美元上調至 90.00 美元，並給予該公司 “持有” 評級。最後，Weiss Ratings 在 12 月 15 日的報告中將 ANI 製藥的評級從 “買入（b-）” 下調至 “持有（c+）”。一位研究分析師給予該股 “強烈買入” 評級，六位分析師給予 “買入” 評級，兩位分析師給予 “持有” 評級。根據 MarketBeat 的數據，ANI 製藥的平均評級為 “適度買入”，平均目標價格為 102.14 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on ANI Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們對 ANI 製藥的最新分析</strong></p>
</div><h2>ANI Pharmaceuticals Stock Down 3.6%</h2>
<div class="lb-trans"><h2>ANI 製藥股票下跌 3.6%</h2>
</div><p>The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of 49.04 and a beta of 0.48. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. The stock has a 50 day moving average price of $86.70 and a 200 day moving average price of $81.62.</p>
<div class="lb-trans"><p>該股市值為 17.9 億美元，市盈率為 49.04，貝塔值為 0.48。公司流動比率為 2.04，當前比率為 2.58，債務股本比率為 1.20。該股的 50 日移動平均價格為 86.70 美元，200 日移動平均價格為 81.62 美元。</p>
</div><p>ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The business had revenue of $227.81 million during the quarter, compared to analyst estimates of $211.92 million. During the same quarter last year, the business earned $1.34 EPS. The firm's quarterly revenue was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.</p>
<div class="lb-trans"><p>ANI 製藥（NASDAQ:ANIP - 獲取免費報告）最近在 11 月 7 日發佈了季度財報。這家專業製藥公司報告每股收益（EPS）為 2.04 美元，超出分析師一致預期的 1.74 美元，超出幅度為 0.30 美元。ANI 製藥的淨利潤率為 4.91%，股本回報率為 26.73%。該公司在本季度的收入為 2.2781 億美元，而分析師預期為 2.1192 億美元。去年同期，該公司每股收益為 1.34 美元。該公司的季度收入同比增長 53.6%。ANI 製藥已將 2025 財年的指導目標設定為每股收益 7.370-7.640 美元。整體來看，分析師預測 ANI 製藥將在當前年度發佈每股收益 3.86 美元。</p>
</div><h2>Institutional Trading of ANI Pharmaceuticals</h2>
<div class="lb-trans"><h2>ANI 製藥的機構交易</h2>
</div><p>Several institutional investors have recently modified their holdings of the business. Intech Investment Management LLC lifted its holdings in shares of ANI Pharmaceuticals by 134.7% in the 2nd quarter. Intech Investment Management LLC now owns 26,917 shares of the specialty pharmaceutical company's stock worth $1,756,000 after purchasing an additional 15,447 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in ANI Pharmaceuticals by 59.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 10,326 shares of the specialty pharmaceutical company's stock valued at $674,000 after purchasing an additional 3,869 shares in the last quarter. Squarepoint Ops LLC acquired a new position in ANI Pharmaceuticals during the second quarter worth $2,137,000. Dynamic Technology Lab Private Ltd acquired a new position in ANI Pharmaceuticals during the second quarter worth $209,000. Finally, Sio Capital Management LLC lifted its stake in shares of ANI Pharmaceuticals by 29.4% in the second quarter. Sio Capital Management LLC now owns 112,923 shares of the specialty pharmaceutical company's stock valued at $7,368,000 after buying an additional 25,625 shares in the last quarter. Institutional investors own 76.05% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者最近調整了對該公司的持股。Intech Investment Management LLC 在第二季度將其在 ANI 製藥的持股增加了 134.7%。Intech Investment Management LLC 目前持有 26,917 股該專業製藥公司的股票，價值 1,756,000 美元，此前在上個季度購買了 15,447 股。Envestnet Asset Management Inc.在第二季度將其在 ANI 製藥的持股增加了 59.9%。Envestnet Asset Management Inc.目前持有 10,326 股該專業製藥公司的股票，價值 674,000 美元，此前在上個季度購買了 3,869 股。Squarepoint Ops LLC 在第二季度獲得了 ANI 製藥的新頭寸，價值 2,137,000 美元。Dynamic Technology Lab Private Ltd 在第二季度獲得了 ANI 製藥的新頭寸，價值 209,000 美元。最後，Sio Capital Management LLC 在第二季度將其在 ANI 製藥的持股增加了 29.4%。Sio Capital Management LLC 目前持有 112,923 股該專業製藥公司的股票，價值 7,368,000 美元，此前在上個季度購買了 25,625 股。機構投資者持有該公司 76.05% 的股票。</p>
</div><h2>ANI Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>ANI 製藥公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.</p>
<div class="lb-trans"><p>ANI 製藥公司是一家總部位於美國的專業製藥公司，專注於仿製藥和品牌處方藥的開發、生產和商業化。該公司作為一個端到端的提供商，提供從活性藥物成分（API）生產和配方開發到成品劑型製造和包裝的服務。</p>
</div><p>ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.</p>
<div class="lb-trans"><p>ANI 的產品組合涵蓋了多個治療領域的注射和口服療法，包括內分泌學、腫瘤學、疼痛管理和呼吸護理。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than ANI Pharmaceuticals</li>
<li>The Fed Pivot Signal Smart Money’s Been Waiting For</li>
<li>This AI–Quantum Company Expects to Hit $274M in Revenue for 2025</li>
<li>Wall Street Stock picker Names #1 Stock of 2026</li>
<li>Do not delete, read immediately</li>
<li>“$6.6 Trillion Of Customer Bank Deposits At Risk”</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 ANI 製藥</li>
<li>美聯儲轉向信號，聰明資金一直在等待</li>
<li>這家 AI-量子公司預計 2025 年收入將達到 2.74 億美元</li>
<li>華爾街股票挑選者命名 2026 年第一隻股票</li>
<li>請勿刪除，立即閲讀</li>
<li>“客户銀行存款 660 億美元面臨風險”</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ANI Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 ANI 製藥嗎？</h2>
</div><p>Before you consider ANI Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 ANI Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 ANI Pharmaceuticals 並不在名單上。</p>
</div><p>While ANI Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 ANI Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

ANI 製藥（NASDAQ:ANIP）因內部人士出售股票導致股價下跌 3.6%